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<ABS>Abstract 
Given the large amount of medical literature of varying methodological quality, care 
must be taken when translating the results of randomized controlled trials into clinical 
practice. To assist in this translation process, we provide a method that involves 
answering three main questions: ‘Can I trust the results?’ ‘How do I understand the 
results?’ and ‘To whom do the results apply?’ To answer the first question, we describe 
important items that help in judging the reliability of the findings. For the second 
question, we address the clinical and statistical significance of results by looking at the 
size and precision of the effect. Finally, we raise the issue of external validity and 
reporting adverse effects to determine which patients may best benefit from the new 
intervention. 
<KEY>Key words: Bias; Evidence-based medicine;Randomization; Randomized 
controlled trial; Sample size; Selection bias 
Given the large amount of medical literature of varying methodological quality, one must 
be careful when transposing the results of a randomized controlled trial (RCT) to clinical 
practice. Here, we give some keys to assess the reliability and understand the results of 
such trials. Because of the wide-ranging fields of medical literature, we focus on two-
group parallel RCTs designed to demonstrate whether one intervention is better than 
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 another. Methodological issues are universal, but as much as possible we try to give 
examples in the field of rheumatology. 
We base our approach to the critical analysis of results of RCTs for translation to clinical 
practice on the systematic approach that Guyatt et al. proposed for critical analysis of 
medical literature.1,2 Our approach is based on three main questions: ‘Can I trust the 
results?’, ‘How do I understand the results?’ and ‘To whom do the results apply?’. To 
help answer the first question, we explain important items that help in judging the 
reliability and validity of the findings. For the second question, we address the clinical 
and statistical significance of results by looking at the size and precision of the effect. 
Finally, we raise the problem of external validity and reporting of adverse effects to 
determine which patients may best benefit from the new intervention. A minimal set of 
items that must be reported to allow for critical analysis of results of an RCT are in the 
CONSORT statement checklist,3 which could be useful for both authors and readers. 
<A>Can I trust the results? 
To evaluate the effect of a treatment, as in many experiments, the best way is to compare 
two groups -- one undergoing the treatment and one not (control group) -- to see which 
has the best outcome. However, for this comparison to be valid and to avoid bias, the 
groups must be similar at baseline, undergo the same care apart from the treatment under 
study and be assessed in the same way at the end of the study. A bias is anything that 
erroneously influences the difference between groups. Specific methods developed to 
overcome sources of bias in clinical trials are summarized in Figure 1, which is adapted 
from Greenhalgh,4 and detailed below. 
<Figure 1 here> 
<B>Were patients randomized and was the randomization concealed? 
Randomizing patients between the treatment and control groups increases the probability 
of obtaining similar patients in the two groups at baseline and thus avoids selection bias. 
Random allocation is the only way to ensure no systematic differences between 
intervention groups in known but also unknown factors that might affect the outcome. 
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 Proper randomization rests on two equally important elements: generation of the 
sequence and its implementation.  
Adequate generation of the sequence usually involves a random-number table or a 
computerized random-number generator. Deterministic allocation methods (sometimes 
called ‘quasi-random’ methods), such as alternation, date of birth or first letter of name, 
are not considered adequate because of their predictability, which allows for the 
scheduling of participants, and the possible correlation between the item used (e.g. 
month of birth, first letter of name) and the outcome. 
When implementing the sequence of randomization, if the allocation is not concealed 
before the patient is assigned to a group, all benefits of randomization are lost. 
Unconcealed randomization can lead to clinicians scheduling patients so that patients 
with particular characteristics receive a certain allocation, thereby biasing the allocation. 
Kunz et al. reviewed all available evidence of the effect of lack of concealment of 
allocation and concluded that studies with inadequate allocation concealment resulted in 
35--40% larger estimates of treatment effect.5 
In the case of indistinguishable treatment and placebo (e.g. same appearance, same 
schedule of administration, same taste), the care provider and the patient are blinded and 
the allocation concealment is self-evident: pre-numbered drugs are administered serially 
by the care provider. In other cases, some approaches that assure adequate concealment 
schemes are as follows: 
<BLF>Centralized randomization (e.g. after patient consent is obtained, the investigator 
calls a 24-hour free-phone service to obtain the allocation group) or pharmacy-controlled 
randomization. 
<BL>Pre-numbered or coded identical, sealed containers administered serially to 
participants. 
<BL>On-site computer system combined with group assignments in a locked unreadable 
computer file that can be assessed only after entering the characteristics of an enrolled 
subject. 
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 <BLL>Sequentially numbered, opaque, sealed envelopes: however, this method has to 
be monitored diligently to ensure that investigators do not open several envelopes 
beforehand and then allocate patients to the desired treatment. 
Proper randomization increases the probability of obtaining similar groups at baseline 
and thus prevents selection bias. However, some differences in baseline characteristics 
between groups may appear because of chance. Important demographic and clinical 
characteristics for each study group should be described so that readers can assess how 
comparable the groups were at baseline for the known prognostic factors. The magnitude 
and direction of the differences are more important than results of significance statistical 
tests in detecting potential subversion of the randomization. Several large differences all 
favouring one group would heighten suspicion about the results of the trial. 
<B>Were patients, care providers and outcome assessors blinded? 
Blinding refers to keeping key people, such as patients, health-care providers (i.e. those 
administering the treatment), and outcome assessors (i.e. those assessing the main 
outcome), unaware of the treatment administered. 
Although the term ‘double blind’ implies that neither the care provider nor the patient 
knows which treatment was received, it is ambiguous in terms of the blinding of other 
people, including those assessing patient outcomes.6 Authors should state and readers 
should carefully assess who was blinded (patients, care providers, outcome assessors, or 
monitors). 
Blinding of patients and health-care providers prevents performance bias. This bias can 
occur if additional therapeutic interventions (i.e. co-interventions) are provided 
preferentially in one of the comparison groups. Blinding guarantees the same follow-up, 
the same attention to the patient, and the same ‘placebo effect’ in the two groups.  
Blinding of outcome assessors minimizes the risk of detection bias. This type of bias 
occurs if patient assignment influences the process of outcome assessment, and it thus 
depends on both the blinding status of the assessor and the nature of the outcome. 
Blinding of outcome assessors is particularly important for subjective outcomes (e.g. 
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 number of inflammatory joints), which entail increased opportunity for bias in 
measurement.7 Objective (hard) outcomes leave less opportunity, if any, for detection 
bias. Knowledge of the intervention would not greatly affect measurement of a hard 
outcome such as death,8 although it might influence subjective assessment such as death 
from cardiovascular causes. For patient-reported outcomes (PRO) such as pain, blinding 
of the outcome assessor implies blinding of the patient. When the two treatments under 
study are indistinguishable (e.g. same characteristics, same schedule of administration, 
same dosage), the blinding of patients, care providers and outcome assessors is easy to 
achieve. If treatments differ, a ‘double-dummy’ procedure may be useful but is not 
always feasible. In a double-dummy procedure, the patients of group A receive drug A 
and a placebo of drug B and patients of group B receive drug B and a placebo of drug A.  
In other situations, clinicians and patients cannot be blinded (e.g. surgery, regimen, 
rehabilitation, or psychotherapy) or blinding seems feasible but cannot be effective (for 
specificity of adverse effects, such as bradycardia with beta-blockers). In these situations, 
methods to blind outcome assessors are particularly useful to avoid detection bias.9 
These methods rely mainly on a centralized assessment of the main outcome, which is 
easy to implement for clinical investigations (e.g. laboratory tests or radiography) or 
clinical events (blinded adjudication committee) but requires more inventive solutions 
for physician-driven data (such as videotaping, audiotaping or photography of clinical 
examination).9,10 
<B>Was follow-up complete and were patients analysed in the groups to which they 
were randomized? 
If a rigorous trial has been undertaken to avoid all the biases that can affect the results of 
the study, an incorrect analytical approach can also introduce bias. In a randomized 
superiority trial, the most robust analytical method that prevents attrition (exclusion) bias 
is the intention-to-treat analysis (ITT).11 An ITT analysis means that all patients are 
analysed in the group to which they were initially randomized, even if they ‘cross over’ 
to the other intervention arm, they discontinue the intervention, or they are lost to follow-
up. This analysis is of particular importance because participants who do not comply 
with the allocated treatment usually do not have the same prognostic factors as those who 
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 comply. For per-protocol or on-treatment analysis, the analysis is restricted to 
participants who fulfil the protocol in terms of eligibility, interventions (treatment 
received) and outcome assessment. In a treatment-received analysis, patients are 
analysed according to the treatment they actually received, regardless of the treatment 
they were originally allocated to receive. Only an ITT analysis ensures that the balance 
in prognostic factors arising from the randomization is maintained.12 An ITT analysis 
answers the question ‘Which choice of treatment is better for the patient?’ and not 
‘Which treatment received is better for the patient?’. Only the former question can be 
answered without bias and, moreover, is the most pragmatic in choosing a treatment. 
Thus, ITT analysis should be the analysis of choice.  
Many authors claim they performed an ITT analysis when in fact they have not: patients 
are excluded from the analysis if they never received any treatment, they were 
randomized but ineligible for the study, or they were lost to follow-up or the outcome 
was not assessed (e.g. arthroscopy not realized). One must check the ITT assumption by 
looking at the flow chart of the progress of patients through the phases of the trial and 
comparing the number of patients randomized to the number analysed (Figure 2). For 
example, in a study comparing three kinds of mattress, patients with low back pain who 
were randomized but who never used their mattress were not included in analysis. The 
conclusion was in favour of the water-bed but the risk of attrition bias is high because the 
rate of dropout was four times as much higher in the water-bed arm than in the two 
others arms.13 
<Figure 2 here> 
The only acceptable exclusions from an analysis are, in a strictly double-blinded study, 
patients who did not receive any treatment; this is usually called modified or quasi ITT 
analysis. Because patients do not know the treatment they will receive, their exclusion is 
unlikely to be due to disillusion in the allocation. If the attrition rate is low and is equally 
distributed between the study arms, the analysis is unlikely to be too biased. 
Performing an ITT analysis usually implies choosing a method to handle missing data. 
Because missing data may occur for various reasons, including adverse events related to 
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 the treatment, the method used for data imputation must be conservative, that is, not 
favour the treatment group.14 
Some studies also report in addition efficacy data for patients willing to continue 
experimental treatment in follow-up extension studies. These results must be interpreted 
with caution because they are of course not analysed under the ITT principle. 
If a large proportion of patients cross over to the opposite treatment arm or are lost to 
follow-up, the interpretation of study results is difficult, and neither an ITT nor a per-
protocol analysis would provide reliable information. An extreme example is the Spine 
Patient Outcomes Research Trial (SPORT) trial, which compares standard open 
diskectomy and non-operative treatment for patients with lumbar intervertebral disk 
herniation; only 60% of patients assigned to surgery received surgery, whereas 45% of 
those assigned to non-operative treatment received surgery.15 Whatever the analysis 
performed, none will be informative. 
<B>Was the outcome appropriate? 
A crucial issue in assessing the results of trials is the actual measure of whether the 
treatment works. The outcome chosen to conclude the effectiveness of the treatment 
could be a clinical event (death, fracture), a therapeutic decision (length of stay, 
transfusion, surgery), a patient-reported outcome (pain) or a result of a complementary 
test (biological or morphological). Most outcomes can be measured as dichotomous 
variables (e.g. event/no event), as continuous variables (e.g. blood pressure, glycaemia, 
Western Ontario and MacMaster Universities Osteoarthritis Index score) or as time to the 
onset of an event (survival time data). Whatever the nature, a good outcome must have 
the following qualities: 
<BLF>clinical relevance 
<BL> good reliability and reproducibility 
<BL>uniqueness 
<BLL>availability for all patients to avoid attrition bias. 
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 In addition, readers should be sceptical of studies involving unconventional outcomes not 
recognized in other studies. 
<B>Clinical relevance and surrogate outcomes 
To decide whether to apply the study results in clinical practice, one needs evidence that 
the treatment studied in an RCT improves outcomes that are important to patients. An 
elevated blood pressure outcome is of minor consequence to the patient, whereas a stroke 
is of major importance.  
Good outcomes that are clinically relevant for the patient are death, length of hospital 
stay, myocardial infarction, fractures, and quality of life. The length of follow-up has to 
be consistent with disease evolution. For example, a follow-up of only 1 month is 
meaningless for a chronic disease. Kyriakidi et al. showed that only 11% of RCTs of 
systemic sclerosis had a follow-up of more than 1 year. 16 
However, these outcomes are usually substituted by ‘surrogate’ outcomes, usually 
biological or imaging markers, which are easier to measure and believed to be indirect 
measures of the clinically relevant outcome. For example, change in bone mineral 
density is often used as a surrogate outcome to measure the effectiveness of treatments 
for the prevention of osteoporotic fractures. 
As well as being of questionable clinical relevance, surrogate outcomes are often 
misleading.17 The effectiveness of the use of sodium fluoride is a good example of a 
misleading conclusion: the treatment substantially increases bone mineral density but 
does not prevent fractures.18 
Surrogate outcomes are widely used because observing a difference in a surrogate 
measure requires a much smaller sample size and shorter follow-up than a clinical 
outcome. Trials designed to observe changes in bone mineral density require only a few 
hundred participants, whereas those designed to observe a fracture endpoint require 
many thousands of participants. However, surrogate outcomes are useful in helping 
guide research at its earliest stages. 
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 <B>Reliability and reproducibility 
A good outcome must be relevant for the patient but also easy to assess. Reliability of a 
study is affected by the reproducibility of the outcome used. For example, assessment of 
joint-space narrowing is more reliable if performed by two trained, independent 
observers and if technical acquisition of radiography is standardized. A measure of 
reproducibility, corrected for agreement by chance, such as the kappa coefficient, helps 
in assessing the quality of the measure: a value > 0.6 implies good agreement and a value 
> 0.8 very good agreement. Where available and appropriate, previously developed and 
validated scales or outcomes should be used, both to enhance quality of measurement 
and to assist in comparison with similar studies. Authors should indicate the origin and 
properties of scales.  
<B>Unique primary outcome 
A single primary outcome must be defined a priori. The study must be designed and the 
sample size calculated to demonstrate whether the treatment has an effect or not on this 
primary outcome. The rationale for this procedure is to avoid a multiplicity of statistical 
tests that can lead to erroneous conclusions because of the risk of hazard. Multiple 
analyses of the same data incur considerable risk of false-positive findings.  
The alpha level is the chance taken by researchers to make a type I error: incorrectly 
declaring a difference to be true because of only chance producing the observed state of 
events. Customarily, the alpha level is set at 0.05, that is, in no more than one in 20 
statistical tests will the test show some effect when in fact no effect exists. If more than 
one statistical test is used, the chance increases of finding at least one test result in the 
whole experiment that is statistically significant due to only chance and to incorrectly 
declare a difference or relationship to be true. In five tests, this chance is 22%; in ten, the 
chance increases to 40%. 
For the same reason, when outcomes are assessed at several time points after 
randomization, the time point of primary interest must also be defined a priori. Many 
trials recruit participants over a long period. If an intervention is working particularly 
well or badly, the study may need to be ended early for ethical reasons. Interim analysis 
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 could be performed. To not bias the overall study results, the interim analysis must be 
planned in advance, statistical methods adapted and results of analysis interpreted by an 
independent committee who may decide or not to stop the study. 
Despite these recommendations, in 2004, Chan et al. found that more than 60% of trials 
had at least one primary outcome that was changed, introduced or omitted between when 
the protocol was approved by a scientific-ethics committee and the publication of the 
results. 19 Protocols, with pre-planned primary outcomes, are now publicly available on 
clinical research registries (e.g. www.clinicaltrials.gov, www.controlled-
trials.com/isrctn) to enable the identification of outcome reporting bias. 
Other outcomes of interest are secondary outcomes. All secondary outcomes must also 
be pre-specified and reported, not just those showing a statistically significant difference 
between groups. Important outcomes must be considered, but a single study must not 
have too many outcomes. 
<B>Were results obtained from subgroup analysis? 
Multiple analyses of the same data incur considerable risk of false-positive findings. As 
previously discussed, this risk should lead to a limitation of the number of outcomes and 
the number of occasions when they are assessed. The same risk is involved in multiple 
analyses of the same outcome in different subgroups of patients. Because of the high risk 
of spurious findings, subgroup analyses do not have good credibility. When considering 
results of a subgroup analysis, the following must be remembered:20 
<BLF>Subgroup analysis should be pre-planned and should be limited to a small number 
of clinically important questions. 
<BL>If important subgroup-treatment-effect interactions are anticipated, trials should 
ideally be powered to detect such interactions reliably. 
<BL>Significance of the effect of treatment in individual subgroups should not be 
reported; rates of false-negative and false-positive results are extremely high. The only 
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 reliable statistical approach is to test for a subgroup-treatment effect interaction, but few 
trials are sufficiently powered to detect this. 
<BL>All subgroup analyses that were done should be reported. 
<BLL>The best test of validity of subgroup-treatment effect interactions is their 
reproducibility in other trials. 
<A>How do I understand the results? 
First, for each outcome, study results should report a summary of the outcome for each 
group (e.g. the proportion of participants with the event, or the mean and standard 
deviation [SD] of measurements).2 Then, to appreciate the treatment effect, two 
additional data must be reported: 
<NL>1. The contrast between the two groups, known as the estimation of treatment 
effect. 
<NL>2. The precision of this estimation, the statistical significance of the treatment 
effect [confidence interval (CI) and/or P value]. 
<B>Estimation of treatment effect 
For a dichotomous outcome, the estimation of treatment effect could be the risk ratio 
[relative risk (RR)], or risk difference [absolute risk reduction (ARR)]; for survival-time 
data, the measure could be the hazard ratio or difference in mean survival time; for 
continuous data, the estimation is usually the difference in means. The P value is useless 
for assessing the size of treatment effect. 
<B>Dichotomous outcome 
Consider, for example, a study in which 20% of patients of a control group died, but only 
15% of patients receiving a new treatment died. The most common way to express the 
impact of treatment would be the RR: the risk of events for patients receiving the new 
treatment relative to the risk for patients in the control group:  
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 <EQN>RR = 0.15/0.20 = 0.75 (= 75%) 
An RR of 0.75 means that the new treatment reduced the risk of death in the treated 
group by 25% (=1 − 0.75) as compared with that in the control group. The closer the RR 
is to 1, the less effective the therapy. In survival analysis, RR is usually computed over a 
period of time and called a hazard ratio. In some statistical computations, particularly 
covariate adjustment, the odds ratio (OR) is computed instead of the RR. The OR is the 
ratio of events to non-events in the intervention group over the ratio of events to non-
events in the control group. An OR can reasonably be interpreted as a RR as long as the 
outcome event is rare.
For some treatments and conditions, the benefit of a specific treatment, as measured by 
the RR, remains approximately constant over patient populations at varying baseline 
risk.20 As a single estimate of treatment effect can be provided for a broad class of 
patients, RR appears attractive. However, it is often clinically important to consider the 
baseline (control) risk of an event before recommending treatment because, for a given 
RR, the expected absolute benefit of treatment could vary considerably as the baseline 
risk changes. For example, an estimated RR of 50% might be important for patients at 
moderate to high risk of a particular adverse event. However, for patients with a low 
probability of an event, the risk reduction might not be sufficient to warrant the toxic 
effects and cost of treatment.21 
Thus, the absolute risk reduction (ARR) could be considered a better measure of 
treatment effect because it reflects the expected absolute benefit, taking into account the 
baseline risk of the patient. The ARR is the difference between the proportion of control 
patients who die and the proportion of treatment patients who die. In our example, the 
ARR is as follows:  
<EQN>ARR = 0.20 − 0.15 = 0.05 = 5% 
For the ARR to be meaningful for clinical practice, its reciprocal, the number needed to 
treat (NNT) is usually used.22 The NNT is the number of patients who would need to be 
treated with the new treatment rather than the standard treatment for one additional 
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 patient to benefit.23 The NNT can be obtained for any trial with a dichotomous 
outcome.The NNT is simply the reciprocal of the ARR: 
<EQN>NNT = 1/ARR 
In our example, the NNT would be 1/0.05 = 20. To prevent one additional death, 20 
patients would need the treatment.  
A large treatment effect, in the absolute scale, leads to a small number needed to treat. A 
treatment that leads to one saved life for every 10 patients treated is clearly better than a 
competing treatment that saves one life for every 50 treated. A correctly specified NNT 
must always give the comparator, the therapeutic outcome, the duration of treatment 
necessary to achieve that outcome, the 95% CI and the baseline risk of event without 
treatment. 
<B>Continuous outcome 
For continuous outcomes, the measure of treatment effect is the difference in means 
between the treatment and control group. The SD reflects the dispersion of values around 
the mean. 
Results for continuous outcomes are usually difficult for clinicians to use in clinical 
practice because of problems in assessing the clinical importance of such outcomes or in 
comparing benefits and risks across various therapeutic options. Dividing the difference 
in means by the SD allows for easier comparison of effects across studies. This ratio is 
called the effect size (ES). For example if the mean score ± SD on a 0--100-mm visual 
analogue scale is 6 ± 2.5 mm in the treatment group and 5.3 ± 2.1 mm in the control 
group, the ES is as follows: 
<EQN>ES = (Mean treatment – Mean control) / SDpooled = (6 − 5.3)/2.3 = 0.3 
Opinions vary on how to interpret effect size, but approximately 0.2 is an indication of a 
small effect, 0.5 a medium effect and 0.8 a large effect size. 
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 Translating a continuous measure (e.g. health assessment questionnaire score, visual 
analogic scale) to a dichotomous measure such as ‘therapeutic success (yes/no)’ usually 
leads to more clinically meaningful results. This dichotomization can help in interpreting 
and assessing the clinical significance of trial results. It allows for an NNT calculation 
that is usually more meaningful than the difference in means. Clinicians would find the 
statement ‘one needs to treat five patients to halve the EVA score in 1 patient’ more 
meaningful than ‘the difference in EVA score between treatment and placebo is 9.7 mm 
(SD = 3.7)’. However, dichotomizing a continuous variable can result in loss of 
information and statistical power. 
<B>Precision of the estimation 
<C>Confidence interval 
Realistically, the true measure of the treatment effect can never be known. The best we 
have is the estimate provided by rigorous controlled trials. This estimate is called a point 
estimate, a single value calculated from observations of the sample. We usually use the 
95% CI to estimate the neighbourhood within which the true effect likely lies; that is, the 
range that includes the true value of the effect 95% of the time. For example, if a trial 
involved 100 patients randomized to the treatment group and 100 to the control group, 
and 15 deaths occurred in the treatment group and 20 in the control group, the authors 
would calculate a point estimate for the RR of 0.75. However, the true RR might be 
much smaller or much greater than this 0.75 with a difference of only five deaths. In fact, 
the treatment might provide no benefit (an RR of 1) or might even do harm (RR > 1). 
And these suppositions would be right. In fact, these results are consistent with both an 
RR of 1.38 (i.e. patients given the new treatment might be 38% more likely to die than 
control patients) and an RR of 0.41 (i.e. patients subsequently receiving the new 
treatment might have a risk of dying almost 60% less than that of non-treated patients). 
In other words, the 95% CI for this RR is (0.41 − 1.38), and one cannot conclude that the 
treatment is better. If the trial enrolled 1000 patients per group, and the same event rates 
were observed, the point estimate of the RR would still be 0.75, but the CI would be 
(0.59 − 0.91), and then one could conclude that the treatment is better. 
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 What these examples show is that the larger the sample size of a trial, the larger the 
number of outcome events, and the greater our confidence that the true RR (or any other 
measure of efficacy) is close to what we have observed. The point estimate -- in this case 
0.75 -- is the one value most likely to represent the true RR. Values farther from the 
point estimate become less consistent with the observed RR. 
When the CI of a ratio contains 1 (or 0 for a difference) the difference is not statistically 
significant and the result is compatible with no effect.  
<C>P value 
Many journals require or strongly encourage the use of CIs, and results should not be 
reported solely as P values.3 Yet CIs are not always reported, and one needs to know 
how to interpret P values. 
Depending on the test used, there are many ways to calculate a P value, but its meaning 
is always the same. The P value shows how often the results would have occurred by 
chance if no difference existed between the two groups. In other words, the P value 
describes the risk of a false-positive conclusion of a difference when, in truth, no 
difference exists.  
The P value reflects the statistical significance of a difference but not its size. A small 
difference observed with a large sample is more significant statistically than the same 
difference observed with a small sample. Thus, a difference could be statistically 
significant but clinically insignificant. The P value tells only if the observed difference is 
likely to be true (P < 0.05) or only the result of chance (P > 0.05), that is, statistically not 
significant. A P < 0.05 means that the result would have arisen by chance in less than 
one occasion in 20; a P > 0.05 means that the CI of the RR does not contain 1. 
<B>Clinical significance vs. statistical significance 
When looking at the results of a study, one must consider two important concepts: 
clinical significance and statistical significance. The former addresses the size of the 
treatment effect and the later its credibility. 
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 The literature is full of statistically significant but clinically insignificant results. A 
clinically significant finding would be one clinically useful for a patient. For example, a 
study might find that a certain medication causes a statistically significant (P < 0.05) 
decrease in blood pressure of 2 mmHg, but this decrease would not be clinically 
significant. By contrast, a finding of a statistically significant decrease in blood pressure 
of 20 mmHg would be more clinically significant. 
Statistical significance depends on the size of the difference between the groups and on 
the number of patients. The P value alone gives no information on the magnitude of the 
effect. Clinically trivial differences can be statistically significant if the sample size is 
sufficiently large. Conversely, clinically important differences can be statistically non-
significant if the sample size is too small, that is, if the study lacks power (Figure 3). As 
an example, Keen et al. found that of 50% of rheumatology reports of RCTs with 
negative or indeterminate results published in 2001--2002, the studies were 
underpowered.24 
<Figure 3 here> 
Sample-size calculation for dichotomous outcomes requires four components: type I 
error (alpha), power, event rate in the control group and a minimal treatment effect of 
interest (or, analogously, an event rate in the treatment group). Calculation of continuous 
outcomes requires, instead of event rate in the control and treatment groups, difference a 
between means and assumptions on the SD. 
The sample size is probably too small if in the calculation one of the following is present: 
<BLF>the clinically relevant minimal treatment effect assumed is too large (a smaller 
but still clinically relevant difference should have been chosen) 
<BL>the event rate in the control group is overestimated 
<BLL>the SD is underestimated for continuous outcomes. 
These over-optimistic assumptions are common because sample size calculation is often 
driven by feasibility. As stated by Guyatt et al., ‘investigators typically decide how many 
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 patients they can feasibly enrol and then find ways of making assumptions that will 
justify embarking on a trial with a feasible sample size’.25 However, underpowered trials 
are not useless because their results contribute to the body of knowledge and are useful 
for meta-analysis. It is difficult to draw conclusions from a single trial, even large ones, 
but provided that the trial is not methodologically biased, the results contribute to the 
larger body of evidence. 
<B>Independence 
Standard methods of analysis assume that the data are ‘independent’. For RCTs, this 
independence usually means that each comparison test involves only one observation per 
participant. Treating multiple observations from one participant as independent data is a 
serious error; such data arise when outcomes can be measured at successive times or 
from different parts of the body, as in rheumatology. For example, in a trial of 
osteoporosis, treating two vertebral fractures in the same patient as two independent 
observations is incorrect. The correct approach is to count the number of patients with at 
least one vertebral facture. Data analysis should be based on counting each participant 
once,26,27 or should involve specific statistical procedures taking into account paired 
data. 
<A>To whom do results apply? 
<B>External validity 
The section ‘Can I trust the results?’ explored only internal validity, that is, the validity 
of the results in the context of the study. If the result is considered reasonably valid, next 
we need to explore the external validity of the result, that is, its validity in other 
contexts.2 Of course, if the study result is not valid, even for the subjects studied, its 
applicability to other groups of subjects is irrelevant.  
There is no external validity per se. The results of a study will never be relevant to all 
patients and all settings, but studies should be designed and their results reported so that 
clinicians can judge to whom the results can reasonably be applied.  
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 The following criteria must be considered before applying results to patients:28 
<BLF>Setting of the trial: country; health-care system; recruitment from primary, 
secondary or tertiary care; selection of participating centres and clinicians. 
<BL>Selection of patients: eligibility and exclusion criteria, ‘run-in’ or ‘washout’ 
period, ‘enrichment’ strategies, ratio of randomized patients to eligible non-randomized 
patients. 
<BL>Characteristics of randomized patients: severity or stage in the natural history of 
disease, co-morbidities, racial group, other baseline clinical characteristics. 
<BL>Difference between trial protocol and routine practice: relevance of control 
intervention, co-interventions, prohibition of certain non-trial treatments, therapeutic or 
diagnostic advances since the trial was performed. 
<BL>Outcome measure and follow-up: clinical relevance of outcomes (e.g. surrogate, 
complex scale, composite outcome), frequency of follow-up, adequacy of the length of 
follow-up. 
<BLL>Adverse effect of treatment: completeness of reporting of adverse effects, rate of 
discontinuation of treatment, selection of trial centres and/or clinicians on the basis of 
skill or experience, exclusion of patients at risk for complications, exclusion of patients 
who experienced adverse effects during a run-in period, intensity of trial safety 
procedure. 
The clinical setting is never exactly the same as the trial setting and the patient often has 
attributes or characteristics different from those enrolled in the trial. These differences 
can result in less benefit, as was shown between a Phase III clinical trial and a Phase IV 
cohort study of the use of etanercept for rheumatoid arthritis.29 So one must ask whether 
these differences might really diminish the treatment response or greatly increase the risk 
of adverse events, that is, ‘Is my patient so different from the study patients that I cannot 
apply the results to my patient?’ 
<B>What are the adverse effects? 
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 Before applying results of a study to a patient, one must consider the possible harm that 
any intervention might do: primum non nocere. Regardless of this crucial information, 
reporting of harms from RCTs has received less attention than reporting of efficacy, and 
is often inadequate. In 2004, an extension of the CONSORT statement focused on better 
reporting of harms-related data from RCTs.30 
Computing the number needed to harm (NNH) and comparing it with the NNT to weigh 
benefits and risks can help to evaluate the usefulness of a treatment. The NNH is the 
average number of subjects receiving treatment that would lead to one additional subject 
having a given adverse event, as compared with the control intervention. The calculation 
of NNH is similar to that of the NNT: 
<EQN>NNH = 1/(proportion of adverse events in the treatment group – proportion of 
adverse events in the control group) 
The following example illustrates how to use NNT and NNH to weigh the benefits and 
risks of a new treatment, according to the characteristics of patients. The results of 
clinical trials suggest that hormone replacement therapy reduces the RR of spine fracture 
over a lifetime by approximately 30%, but such therapy also increases the risk of stroke 
by 50%. Consider two menopausal women with different baseline expected rates of spine 
fracture and stroke: patient A has low bone mineral density but no cardiovascular risk 
factors; patient B has normal bone mineral density but many cardiovascular risk factors. 
Table 1 summarizes the NNT and NNH values for these two women. Treating 
approximately 200 women such as patient A during 2 years will prevent twelve spine 
fractures (200/17) but induce one stroke. Given the small increased risk of stroke and the 
number of spine fractures prevented, many clinicians might suggest hormone 
replacement therapy for such patients. By contrast, treating approximately 200 women 
such as patient B during 2 years will prevent only six spine fractures (200/33) but will 
induce three strokes. Obviously, hormone replacement therapy is less indicated in these 
patients. 
<Table 1 here> 
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 Looking at the rate of adverse effects reported in each group helps when appraising the 
risks of a treatment. However, studies seldom, if ever, have enough power to detect a 
statistically significant difference between groups in these rates. Sample sizes are usually 
too small for a reasonable chance of detecting an unexpected adverse effect. Therefore, 
some authors suggest the creation of a composite outcomes basket to be used as the 
primary safety outcome in clinical effectiveness trials.31 
<B>Conflict of interest 
Last, but not least, another piece of information of importance when reading an article of 
the results of an RCT is the study funding. An article reporting industry-supported study 
results could be less objective than one reporting an academic-supported study. For 
example, in a review of results of trials comparing non-steroidal anti-inflammatory drugs 
(NSAIDs) used in the treatment of arthritis, Rochon et al. showed that the manufacturer-
associated NSAID was almost always reported as being equal or superior in efficacy and 
lack of toxic effects to the comparison NSAID.32 
<PP>Practice points 
<BLF>Patient assignment to groups of treatment must be characterized by 
unpredictability: allocation randomized and concealed until patients are assigned to a 
group. 
<BL>Blinding is the best way to avoid performance and detection bias. Studies should 
clearly state who was blinded (care providers, patients, outcome assessors and/or data 
analysts), except when it is obvious than everyone is blinded (if the two treatments are 
really indistinguishable). 
<BL>Intention-to-treat analysis is the most robust analytical method. All patients are 
analysed in the group to which they were initially randomized, even if they cross over to 
the other intervention arm, they discontinued the intervention or they are lost to follow-
up. 
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 <BL>The primary outcome must be unique, be clinically relevant, be available for all 
patients, have a good reliability and reproducibility and be used for sample size 
calculations. 
<BLL>Study results should report both a measure of treatment effect and an estimation 
of the precision of this measure. Readers need to critically appraise the statistical and 
clinical significance of a result. 
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Table 1 Risk of spine fracture or stroke with and without HRT, relative risk, 
absolute risk reduction or increase and NNT or NNH for two profiles of patient. Patient 
A has low bone mineral density but no cardiovascular risk factors; patient B has normal 
bone mineral density but many cardiovascular risk factors 













Spine fracture 0.20 0.14 0.70 0.06 17 Patient A 
Stroke  0.01 0.015 1.5 0.005 200 
Spine fracture 0.10 0.07 0.70 0.03 33 Patient B 
Stroke  0.03 0.045 1.5 0.015 67 
<TFN>HRT: hormone replacement therapy; NNT: number needed to treat; NNH: 
number needed to harm 
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 Figure 1 Sources of bias in randomised controlled trials and methods to overcome 
them. 
Figure 2 Flow chart of participants through each stage of a randomised controlled 
trial. 
Figure 3 Clinical significance and interpretation of the P value. 
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